Update on the safety of testosterone therapy in cardiac disease

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 697-704

  Aaronson, Alistair J ^a,b   Morrissey, Ryan P ^a,b   Nguyen, Cam T ^a,b   Willix, Robert ^a,b   Schwarz, Ernst R ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cenegenics Medical Institute   (United States)

Author keywords

cardiovascular disease; coronary heart disease; dyslipidemia; heart failure; hypogonadism; testosterone

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE UNDECANOATE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOCARDIOGRAPHY; CACHEXIA; CANCER INCIDENCE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSLIPIDEMIA; HEART FAILURE; HEMATOCRIT; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MEDLINE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHYSICAL CAPACITY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT DEPRESSION; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TESTOSTERONE;

EID: 80051957410     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.566213     Document Type: Review

References (45)

1. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5(12):673-81
2. Jones TH. Testosterone deficiency: A risk factor for cardiovascular disease? Trends Endocrinol Metab 2010;21(8):496-503
3. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 2008;28(12):1511-22
4. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 2009;210(1):232-6
5. Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: The lipid link. Vascul Pharmacol 2009;51(5-6):303-13
6. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21(11):890-4
7. Sieminska L, Wojciechowska C, Swietochowska E, et al. Serum free testosterone in men with coronary artery atherosclerosis. Med Sci Monit 2003;9(5):CR162-6
8. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007;19(2):176-82
9. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31(12):1494-501
10. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96(22):1821-5
11. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99(20):1516-24
12. Khaw KT, Dowsett M, Fokerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective population study. Circulation 2007;116(23):2694-701
13. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 1988;78(3):539-45
14. Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb 1993;13(4):517-20
15. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol (Oxf ) 2005;63(3):280-93
16. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: Results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010;7(10):3495-503
17. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor. Circulation 2007;116(21):2427-34
18. Shabsigh R, Katz M, Yan G, Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005;96(12B):67M-72M
19. Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf ) 2010;73(5):602-12
20. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: Potential benefits and risks. J Am Geriatr Soc 2003;51(1):101-15, discussion 15
21. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000;102(16):1906-11
22. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977;39(11):1217-22
23. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96(2):526-34
24. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54(10):919-27
25. Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006;27(1):57-64
26. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: A pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010;56(16):1310-16
27. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88(16):1118-26
28. Ling S, Dai A, Williams MR, et al. Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology 2002;143(3):1119-25
29. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol 2004;6(Suppl 6):S22-9
30. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89(5):2085-98
31. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006;102(1-5):261-6
32. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: What is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9(1):14-18
33. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 1998;41(1):1-15
34. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol 2010;106(6):893-901
35. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 2003;24(10):909-15
36. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109-22
37. O'Connell MD, Roberts SA, Srinivas-Shankar U, et al. Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men? J Clin Endocrinol Metab 2010. [Epub ahead of print]
38. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: A systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(6):2560-75
39. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82(1):29-39
40. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359(19):2005-17
41. Basaria S, Dobs AS. Safety and adverse effects of androgens: How to counsel patients. Mayo Clin Proc 2004;79(Suppl 4):S25-32
42. Shufelt CL, Braunstein GD. Safety of testosterone use in women. Maturitas 2009;63(1):63-6
43. Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res 2010;12(6):R98
44. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7(11):3758-64
45. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95(6):2536-59